Effective venetoclax-based treatment in relapsed/refractory multiple myeloma patients with translocation t(6;14)
In this study, we conducted a retrospective analysis to investigate the efficacy of venetoclax-based therapy in relapsed/refractory myeloma patients with t(6;14) translocation. The treatment courses of three patients, that included previous therapies and responses to venetoclax, were assessed. Clinical data, laboratory results, and adverse events were analyzed to evaluate treatment outcomes. Results: Our findings demonstrated remarkable therapeutic responses in three consecutive patients with t(6;14) translocation-associated myeloma who received venetoclax-based therapy. Patient 1, a lenalidomide-bortezomib-daratumumab and...
Source: Pathology Oncology Research - November 29, 2023 Category: Pathology Authors: Andrea Cegl édi Zolt án Csukly M ónika Fekete Andr ás Kozma Zsuzsanna Szemlaky Hajnalka Andrikovics G ábor Mikala Source Type: research
A Polyherbal Ashwagandha Formulation Exhibits Adjunctive Antitumor Efficacy Against U266 Myeloma Cells by Multi-Strategic Cytotoxic Effects: An Experimental Approach
Conclusion: Habb-e-asgandh formulation possess anti-tumorigenic efficacy against multiple myeloma. The adjunctive Habb-e-asgandh formulation with standard chemotherapeutic drug may prove to be a potent anti-myeloma agent in interventional therapy for Multiple myeloma if further studied in future avenues.PMID:38019228 | DOI:10.31557/APJCP.2023.24.11.3705 (Source: Asian Pacific Journal of Cancer Prevention)
Source: Asian Pacific Journal of Cancer Prevention - November 29, 2023 Category: Cancer & Oncology Authors: Shraddha Kapoor Nidhi Gupta Alpana Sharma Source Type: research
Effective venetoclax-based treatment in relapsed/refractory multiple myeloma patients with translocation t(6;14)
In this study, we conducted a retrospective analysis to investigate the efficacy of venetoclax-based therapy in relapsed/refractory myeloma patients with t(6;14) translocation. The treatment courses of three patients, that included previous therapies and responses to venetoclax, were assessed. Clinical data, laboratory results, and adverse events were analyzed to evaluate treatment outcomes. Results: Our findings demonstrated remarkable therapeutic responses in three consecutive patients with t(6;14) translocation-associated myeloma who received venetoclax-based therapy. Patient 1, a lenalidomide-bortezomib-daratumumab and...
Source: Pathology Oncology Research - November 29, 2023 Category: Pathology Authors: Andrea Cegl édi Zolt án Csukly M ónika Fekete Andr ás Kozma Zsuzsanna Szemlaky Hajnalka Andrikovics G ábor Mikala Source Type: research
A Polyherbal Ashwagandha Formulation Exhibits Adjunctive Antitumor Efficacy Against U266 Myeloma Cells by Multi-Strategic Cytotoxic Effects: An Experimental Approach
Conclusion: Habb-e-asgandh formulation possess anti-tumorigenic efficacy against multiple myeloma. The adjunctive Habb-e-asgandh formulation with standard chemotherapeutic drug may prove to be a potent anti-myeloma agent in interventional therapy for Multiple myeloma if further studied in future avenues.PMID:38019228 | DOI:10.31557/APJCP.2023.24.11.3705 (Source: Asian Pacific Journal of Cancer Prevention)
Source: Asian Pacific Journal of Cancer Prevention - November 29, 2023 Category: Cancer & Oncology Authors: Shraddha Kapoor Nidhi Gupta Alpana Sharma Source Type: research
Effective venetoclax-based treatment in relapsed/refractory multiple myeloma patients with translocation t(6;14)
In this study, we conducted a retrospective analysis to investigate the efficacy of venetoclax-based therapy in relapsed/refractory myeloma patients with t(6;14) translocation. The treatment courses of three patients, that included previous therapies and responses to venetoclax, were assessed. Clinical data, laboratory results, and adverse events were analyzed to evaluate treatment outcomes. Results: Our findings demonstrated remarkable therapeutic responses in three consecutive patients with t(6;14) translocation-associated myeloma who received venetoclax-based therapy. Patient 1, a lenalidomide-bortezomib-daratumumab and...
Source: Pathology Oncology Research - November 29, 2023 Category: Pathology Authors: Andrea Cegl édi Zolt án Csukly M ónika Fekete Andr ás Kozma Zsuzsanna Szemlaky Hajnalka Andrikovics G ábor Mikala Source Type: research
A Polyherbal Ashwagandha Formulation Exhibits Adjunctive Antitumor Efficacy Against U266 Myeloma Cells by Multi-Strategic Cytotoxic Effects: An Experimental Approach
Conclusion: Habb-e-asgandh formulation possess anti-tumorigenic efficacy against multiple myeloma. The adjunctive Habb-e-asgandh formulation with standard chemotherapeutic drug may prove to be a potent anti-myeloma agent in interventional therapy for Multiple myeloma if further studied in future avenues.PMID:38019228 | DOI:10.31557/APJCP.2023.24.11.3705 (Source: Asian Pacific Journal of Cancer Prevention)
Source: Asian Pacific Journal of Cancer Prevention - November 29, 2023 Category: Cancer & Oncology Authors: Shraddha Kapoor Nidhi Gupta Alpana Sharma Source Type: research
Effective venetoclax-based treatment in relapsed/refractory multiple myeloma patients with translocation t(6;14)
In this study, we conducted a retrospective analysis to investigate the efficacy of venetoclax-based therapy in relapsed/refractory myeloma patients with t(6;14) translocation. The treatment courses of three patients, that included previous therapies and responses to venetoclax, were assessed. Clinical data, laboratory results, and adverse events were analyzed to evaluate treatment outcomes. Results: Our findings demonstrated remarkable therapeutic responses in three consecutive patients with t(6;14) translocation-associated myeloma who received venetoclax-based therapy. Patient 1, a lenalidomide-bortezomib-daratumumab and...
Source: Pathology Oncology Research - November 29, 2023 Category: Pathology Authors: Andrea Cegl édi Zolt án Csukly M ónika Fekete Andr ás Kozma Zsuzsanna Szemlaky Hajnalka Andrikovics G ábor Mikala Source Type: research
A Polyherbal Ashwagandha Formulation Exhibits Adjunctive Antitumor Efficacy Against U266 Myeloma Cells by Multi-Strategic Cytotoxic Effects: An Experimental Approach
Conclusion: Habb-e-asgandh formulation possess anti-tumorigenic efficacy against multiple myeloma. The adjunctive Habb-e-asgandh formulation with standard chemotherapeutic drug may prove to be a potent anti-myeloma agent in interventional therapy for Multiple myeloma if further studied in future avenues.PMID:38019228 | DOI:10.31557/APJCP.2023.24.11.3705 (Source: Asian Pacific Journal of Cancer Prevention)
Source: Asian Pacific Journal of Cancer Prevention - November 29, 2023 Category: Cancer & Oncology Authors: Shraddha Kapoor Nidhi Gupta Alpana Sharma Source Type: research
Effective venetoclax-based treatment in relapsed/refractory multiple myeloma patients with translocation t(6;14)
In this study, we conducted a retrospective analysis to investigate the efficacy of venetoclax-based therapy in relapsed/refractory myeloma patients with t(6;14) translocation. The treatment courses of three patients, that included previous therapies and responses to venetoclax, were assessed. Clinical data, laboratory results, and adverse events were analyzed to evaluate treatment outcomes. Results: Our findings demonstrated remarkable therapeutic responses in three consecutive patients with t(6;14) translocation-associated myeloma who received venetoclax-based therapy. Patient 1, a lenalidomide-bortezomib-daratumumab and...
Source: Pathology Oncology Research - November 29, 2023 Category: Pathology Authors: Andrea Cegl édi Zolt án Csukly M ónika Fekete Andr ás Kozma Zsuzsanna Szemlaky Hajnalka Andrikovics G ábor Mikala Source Type: research
A Polyherbal Ashwagandha Formulation Exhibits Adjunctive Antitumor Efficacy Against U266 Myeloma Cells by Multi-Strategic Cytotoxic Effects: An Experimental Approach
Conclusion: Habb-e-asgandh formulation possess anti-tumorigenic efficacy against multiple myeloma. The adjunctive Habb-e-asgandh formulation with standard chemotherapeutic drug may prove to be a potent anti-myeloma agent in interventional therapy for Multiple myeloma if further studied in future avenues.PMID:38019228 | DOI:10.31557/APJCP.2023.24.11.3705 (Source: Asian Pacific Journal of Cancer Prevention)
Source: Asian Pacific Journal of Cancer Prevention - November 29, 2023 Category: Cancer & Oncology Authors: Shraddha Kapoor Nidhi Gupta Alpana Sharma Source Type: research
